A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010 Feb 24; 8:20.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Estramustine
Humans
Interferons
Isotretinoin
Male
Middle Aged
Mitoxantrone
Neoplasm Metastasis
Paclitaxel
Prostatic Neoplasms
Proto-Oncogene Proteins c-bcl-2
Quality of Life
Survival Rate
Teratogens
Treatment Outcome
Vinblastine